Conference Proceedings

A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

Ezra EW Cohen, Danny Rischin, David G Pfister, Jan Baptist Vermorken, Yufan Zhao, Hema Gowda, Joy Yang Ge, Fan Jin, Kevin J Harrington

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2018